UK Inquest Exposes Diagnostic Trap: Mounjaro Side Effects Mimic Bowel Perforation

Account Manage Account Logout Home Health Medicine UK Inquest Exposes Diagnostic Trap: Mounjaro Side Effects Mimic Bowel Perforation Clinicians’ side-effect diagnosis led to fatal discharge; MHRA GLP-1 adverse reports now top 158,000 By Jos

Account

Manage Account

Logout Home

Health

Medicine

UK Inquest Exposes Diagnostic Trap: Mounjaro Side Effects Mimic Bowel Perforation Clinicians’ side-effect diagnosis led to fatal discharge; MHRA GLP-1 adverse reports now top 158,000 By Joshua Mitchell Published: Aug 07 2026, 8:58 AM EDT A Norfolk coroner's inquest is actively examining how Mounjaro's known gastrointestinal side effects may have caused hospital clinicians to discharge a 73-year-old woman hours before she died of a perforated bowel a case that crystallizes a systemic risk now backed by 158,985 adverse-reaction reports filed with the UK's medicines regulator.

The MHRA Yellow Card scheme shows that across three GLP-1 weight-loss drugs, 216 reports were associated with deaths.

The inquest into the death of Caroline Savage, of Wortwell, Norfolk, heard that when she arrived at Norfolk and Norwich University Hospital on October 18, 2024, in acute abdominal pain, clinicians performed blood tests and an ultrasound but not a CT scan.

Constipation and abdominal pain are recognized side effects of Mounjaro, and the treatment team used those side effects as a working diagnosis.

Savage had been taking Mounjaro on a private prescription since July 2024 and had just increased her dose from 7.5mg to 10mg.

She was discharged that evening.

Shortly after midnight, her husband found her collapsed at home.

A post-mortem examination found she had died from fecal peritonitis caused by a perforation of her intestines.

Details of the inquest proceedings were reported by multiple outlets.

Savage had lost approximately two stone about 28 lbs over four months.

The coroner has not yet issued a final conclusion, and no established evidence directly links Mounjaro to fecal peritonitis.

But the hearing was told that a specific pharmacological pathway could theoretically connect the two: Mounjaro slows the rate at which food and waste move through the gastrointestinal tract, and constipation is a known consequence.

For a patient with undiagnosed diverticular disease small, weak pouches in the colon wall that affect up to 60% of adults over age 60 in Western countries elevated intestinal pressure from slowed motility could theoretically increase the risk of inflammation and perforation, medical evidence presented at the inquest suggested.

The quantitative impact, expert testimony noted, cannot be determined.

Information on GLP-1 risks in diverticular disease has been reviewed by multiple clinical commentators.

The family is represented by barrister Jasmine Leng, who argued that Savage's symptoms should have prompted further investigation rather than being attributed to the drug's known side-effect profile.

That clinical attribution question when does severe abdominal pain in a GLP-1 user signal a drug side effect, and when does it signal something requiring surgical imaging?

sits at the center of the inquest's examination.

The Medicines and Healthcare products Regulatory Agency MHRA data released this week through its Yellow Card scheme shows that Mounjaro tirzepatide, made by Eli Lilly accounts for the large majority of all GLP-1 adverse-reaction reports.

Of the 106,309 Yellow Card reports filed against Mounjaro, 11,554 were classified as serious and 120 were death-associated.

Wegovy semaglutide, Novo Nordisk contributed 48,148 reports, of which 5,682 were serious and 59 were deaths.

Saxenda liraglutide, also Novo Nordisk added 4,528 reports, with 1,119 serious and 37 fatal outcomes.

The three-drug total: 158,985 reports, 18,355 serious, and 216 death-associated reports.

Mounjaro's outsized share is consistent with its dominance in the UK private market: a UCL study published in BMC Medicine in January 2026 estimated that approximately 1.6 million adults across England, Wales, and Scotland used a GLP-1 drug for weight loss between early 2024 and early 2025, and four out of five of those using the drugs solely for weight loss reported taking Mounjaro.

Mounjaro typically costs around 200 per month approximately $269 USD on a private prescription in the UK.

These figures represent a dramatic acceleration from data available 13 months earlier.

When law firm Clyde & Co extracted Yellow Card data on June 27, 2025, tirzepatide had accumulated 20,882 adverse reaction reports and semaglutide 18,046 together roughly 41,000 reports.

Today's combined total of 158,985 represents a nearly fourfold increase over that baseline, and Mounjaro's figures specifically increased roughly fivefold.

The primary drivers are not a sudden worsening of the drugs' actual safety profile but the dramatic expansion of prescribing volumes and growing public and medical awareness of the reporting system.

Understanding the MHRA data requires understanding what the Yellow Card scheme was designed to do and what it cannot do.

The Yellow Card scheme is the world's first spontaneous adverse drug reaction reporting system, established in 1964 in the immediate aftermath of the thalidomide tragedy.

Under the Yellow Card scheme's guidance, patients, caregivers, pharmacists, physicians, coroners, pharmaceutical companies, and other regulators can submit reports linking a medicine to a suspected adverse reaction.

The reports are voluntary.

The scheme's designers, led by Professor Bill Inman, understood from the start that voluntary reporting would capture only a fraction of actual adverse events.

Research has consistently confirmed that estimate: a 2006 systematic review of 37 studies across 12 countries found a median underreporting rate of 94%, suggesting that fewer than one in ten serious adverse reactions are ever reported to spontaneous surveillance systems.

The underreporting dynamic has a double edge for the current data.

On one hand, it means the 216 death-associated reports almost certainly undercount the total number of deaths in which GLP-1 drugs may have played some role.

On the other hand and the MHRA has been explicit about this the presence of a death-associated report does not establish that the drug caused the death.

The same inquest that links Mounjaro to Savage's death also notes no established causal evidence.

The agency confirmed it takes all fatal reports extremely seriously and assesses them against post-marketing data and peer-reviewed publications adding that the drugs' benefit-risk profile remains favorable for appropriate patient populations.

Multiple reports may also refer to the same individual a patient, their family member, their physician, and their hospital may all file separate Yellow Cards on the same adverse event.

The total count is a count of reports, not a count of individuals or confirmed causal outcomes.

The mechanism connecting Mounjaro to gastrointestinal complications begins with what the drug is designed to do.

Tirzepatide is a dual receptor agonist: it activates both GLP-1 glucagon-like peptide-1 and GIP glucose-dependent insulinotropic polypeptide receptors simultaneously, mimicking two gut hormones at once.

GLP-1 activation slows gastric emptying the rate at which food moves from the stomach into the intestine and suppresses appetite.

GIP activation adds further insulin-stimulating effects and is believed to enhance the drug's fat-loss properties through effects on adipose tissue.

The combination of both targets is why tirzepatide produces greater average weight loss roughly 22% of body weight in clinical trials than semaglutide roughly 1521% , which activates GLP-1 receptors only.

The price of slowing gastric motility is its effect further down the digestive tract.

Slower transit means longer time for intestinal contents to compact, and constipation is among the drug's most commonly reported side effects.

In patients with a history of inflammatory bowel disease, prior GI surgery, or diverticulosis, that slowed motility can become clinically significant.

Dr.

Qin Rao, quoted in a December 2024 medical analysis, outlined the risk: patients with diverticulosis, chronic constipation, IBD, or prior GI surgeries should use GLP-1 agonists cautiously since intestinal obstruction increases the risk of perforation.

Diverticular disease is not rare.

Small pouches diverticula in the colon wall affect an estimated 35% of adults under 50 and up to 60% of those over 60 in Western countries, according to clinical guidance on GLP-1 use in this population.

Most people with diverticulosis have no symptoms and no diagnosis.

That is the clinical context the Savage inquest has surfaced: a patient who was managing obesity and lipoedema, taking a drug with well-documented GI effects, who had a structural vulnerability that was undetected until a post-mortem.

An American College of Gastroenterology case series presented in 2025 documented at least one additional case of bowel perforation in a patient on a GLP-1 receptor agonist who had pre-existing diverticulosis.

A 2026 review of published literature and litigation data found that observational analyses and case reports show an association between GLP-1 therapy and increased rates of bowel obstruction and other serious intestinal complications, though causation has not been definitively established for the most severe outcomes.

Australian Woman's Tragic Death Linked to Popular Weight Loss Drug Ozempic The Savage case has a structural context that the Yellow Card data cannot capture: she was on a private prescription, which means her care sat almost entirely outside the NHS monitoring infrastructure.

An estimated 90% of UK patients currently using GLP-1 drugs for weight loss access them through private prescriptions, according to the Food Foundation's January 2026 survey of GLP-1 use.

The NHS is conducting a phased rollout of Mounjaro for obesity that initially aimed to reach only 220,000 patients over three years from June 2025 against an estimated 3.4 million adults who meet eligibility criteria, and a UCL study estimating 1.6 million were already using the drugs for weight loss in the year before the NHS rollout formally began.

That gap between NHS capacity and actual use has created a large private market with variable levels of clinical oversight.

A January 2026 survey of 540 general practitioners by the Medical and Dental Defence Union of Scotland MDDUS found that 78% were concerned about patients receiving GLP-1 drugs without proper consultation or review of medical records, 75% were concerned about a lack of monitoring to ensure patient safety, and 57% flagged limited communication between private providers and NHS practices.

A Pulse Today report on the MDDUS survey found similar patterns.

A February 2026 Health Foundation analysis of 113,630 patients using privately prescribed GLP-1 drugs found that access skewed sharply toward affluent areas, with per-person prescribing rates roughly 32% lower in the most deprived areas despite those areas having nearly double the obesity prevalence.

The Yellow Card scheme is open to all private patients, private providers, and NHS staff alike can submit reports.

But private providers operating with limited communication to NHS records are less likely to cross-reference a patient's GI history, flag contraindications, or follow up on adverse event reporting the way NHS pathways are designed to.

When Savage's clinicians at Norfolk and Norwich University Hospital attributed her acute abdominal pain to Mounjaro's side effects, they may not have had access to any record of underlying diverticular disease because it had never been diagnosed.

That is not a failure of the Yellow Card scheme; it is a failure of the clinical infrastructure around private prescribing to provide the information clinicians need to make accurate differential diagnoses.

GLP-1 Fraud: Asheville Wellness Owner Charged With Distributing Unlicensed Tirzepatide Pancreatitis is the GLP-1 adverse eve

Peptides referenced: Semaglutide, Tirzepatide, Liraglutide, Glucagon, GLP-1.